Treatment of psoriatic arthritis with etanercept, a tumour necrosis factor antagonist

Bibliography

• GLADMAN DD: Psoriatic arthritis. Dermatol Ther. (2004) 17:350–363.
   PubMedGoogle Scholar
• MEASE PJ: Recent advances in the management of psoriatic arthritis. Curr. Opin. Rheumatol (2004) 16:366–370.
   PubMed Web of Science ®Google Scholar
• KREUGER G, CALLIS K: Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis. Arch. Dermatol (2004) 140:218–225.
   PubMed Web of Science ®Google Scholar
• MEASE PJ, ANTONI CE: Psoriatic arthritis treatment: biological response modifiers. Ann. Rheum. Dis. (2004) 64(Suppl. II):ii78-ii82.
   Google Scholar
• •A brief review of the TNF-a antagonists for the treatment of PsA.
   Google Scholar
• CENTOCOR, INC.: Remicade (infliximab) [prescribing information]. Malvern, PA, USA (2005).
   Google Scholar
• NASH P, CHEGG DO: Psoriatic arthritis therapy: NSAIDs and traditional DMARDS. Ann. Rheum. Dis. (2005) 64\(Suppl. 2):ii74-ii77.
   Google Scholar
• KYLE S, CHANDLER D, GRIFFITHS CE et al.: Guideline for anti-TNF-a therapy in psoriatic arthritis. British Society for Rheumatology Standards Guidelines Audit Working Group (SGAWG). Rheumatology (Word) (2005) 44:390–397.
   PubMed Web of Science ®Google Scholar
• LEBWOHL M: Use of etanercept in the dermatology setting: a review. Am. J. Clin. Dermatol (2005) 6:49–59.
   PubMed Web of Science ®Google Scholar
• GOTTLIEB AB, ANTONI CE: Treating psoriatic arthritis: how effective are TNF antagonists? Arthritis Res. Ther. (2004) 6\(Suppl. 2):531–535.
   Google Scholar
• ANTONI C, DECHANT C, HANNS-MARTIN LORENZ PD et al: Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum. (2002) 47:506–512.
   PubMed Web of Science ®Google Scholar
• CAUZA E, SPAK M, CAUZA K, HANUSCH-ENSERER U, DUNKY A, WAGNER E: Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab. Rheumatol Int. (2002) 22:227–232.
   PubMed Web of Science ®Google Scholar
• ANTONI CE, KAVANAUGH A, KIRKHAM B et al: Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis. Arthritis Rheum. (2005) 52:1227–1236.
   PubMed Web of Science ®Google Scholar
• ANTONI C, KRUEGER GG, DE VLAM K et al: Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. For the IMPACT 2 investigators. Ann. Rheum. Dis. (2005) 64:1150–1157.
   PubMed Web of Science ®Google Scholar
• CHEW AL, BENNETT A, SMITH CH, BARKER J, KIRKHAM B: Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab. Br. J. Dermatol (2004) 151:492–496.
   PubMed Web of Science ®Google Scholar
• MEASE P, GLADMAN D, RITCHLIN C, RUDERMAN E, STEINFELD D, CHOY E et al: Adalimumab therapy in patients with psoriatic arthritis: 24-week results of a Phase III study. Arthritis Rheum. (2004) 50:4097.
   Web of Science ®Google Scholar
• ANANDARAJAH A, RITCHLIN CT: Treatment update on spondyloarthropathy. Curr. Opin. Rheumatol (2005) 17:247–256.
   PubMed Web of Science ®Google Scholar
• IMMUNEX CORPORATION: Enbrel (etanercept) [prescribing information]. Thousand Oaks, CA, USA (2005).
   Google Scholar
• GOFFE B, GATHER JC: Etanercept: an overview. J. Am. Acad. Dermatol (2003) 49:5105–5111.
   Google Scholar
• SUFFREDINI AF, REDA D, BANKS SM, TROPEA M, AGOSTI JM, MILLER R: Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J. Immunol (1995) 155:5038–5045.
   PubMed Web of Science ®Google Scholar
• ZHOU H: Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. J. Clin. Pharmacol (2005) 45:490–497.
   PubMed Web of Science ®Google Scholar
• NESTOROV I: Clinical pharmacokinetics of tumor necrosis factor antagonists. Rheumatol (2005) 32\(Suppl. 74):13–18.
   Google Scholar
• NI L, SHEELO C, SALFI M, PELOSO P, SULLIVAN JT: Comparative pharmacokinetics (PK) of a single 50-mg injection of subcutaneous (SC) liquid etanercept versus 2 x 25 mg SC lyophilized etanercept. Poster presentation. 2004 American College of Rheumatology Annual Scientific Meeting. San Antonio, TX, USA (16–21 October 2004) 1494.
   Google Scholar
• MEASE PJ, GOFFE BS, METZ J, VANDERSTOEP A. FINCK B, BURGE DJ: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet (2000) 356:385–390.
   PubMed Web of Science ®Google Scholar
• GOTTLIEB AB: Etanercept for the treatment of psoriasis and psoriatic arthritis. Dermatol Ther. (2004) 17:401–408.
   PubMedGoogle Scholar
• •An excellent review of the Phase II and III clinical trial results.
   Google Scholar
• MEASE PJ, KIVITZ AJ, BURGH FX et al.: Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. (2004) 50:2264–2272.
   PubMed Web of Science ®Google Scholar
• MEASE PJ: Etanercept, a TNF antagonist for treatment of psoriatic arthritis and psoriasis. Skin Ther. Lett. (2003) 8:1–4.
   PubMedGoogle Scholar
• KEYSTONE EC: Safety of biologic therapies - an update. J. Rheumatol (2005) 32\(Suppl. 74):8–12.
   Google Scholar
• LEE JH, SLIFMAN NR, GERSHON SK et al.: Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum. (2002) 46:2565–2570.
   PubMed Web of Science ®Google Scholar
• GONZALEZ-VICENT M, DIAZ MA, SEVILLA J, MADERO L: Cerebral toxoplasmosis following etanercept treatment for idiophatic pneumonia syndrome after autologous peripheral blood progenitor cell transplantation (PBPCT). Ann. Hematol (2003) 82:649–653.
   PubMed Web of Science ®Google Scholar
• GOTTLIEB GS, LESSER CF, HOLMES KK, WALD A: Disseminated sporotrichosis associated with treatment with immunosuppressants and tumor necrosis-factor alpha antagonists. Clin. Infect. Dis. (2003) 37:838–840.
   PubMed Web of Science ®Google Scholar
• LASSOUED S, SIRES, FARNY M, BILLEY T, LASSOUED K: Pulmonary aspergillosis in a patient with rheumatoid arthritis treated by etanercept. Clin. Exp. Rheumatol (2004) 22:267–268.
   PubMed Web of Science ®Google Scholar
• MOHAN AP, COTE TR, BLOCK JA, MANADAN AM, SIEGEL JN, BRAUN MM: Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin. Infect. Dis. (2004) 39:295–299.
   PubMed Web of Science ®Google Scholar
• MACHOLD KP, SMOLEN JS: Adalimumab - a new TNF-a antibody for treatment of inflammatory joint disease. Expert Opin. Biol. Ther. (2003) 3:351–360.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Targeted tuberculin skin testing and treatment of latent tuberculosis infection. American Thoracic Society (ATS) and Centers for Disease Control and Prevention (CDC), Am. J. Respir. Crit. Care Med. (2000) 161:S221–S247.
   Google Scholar
• NO AUTHORS LISTED: TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology (1999) 53:457–465.
   Google Scholar
• MOHAN N, EDWARDS ET, CUPPS TR et al.: Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. (2001) 44:2862–2869.
   PubMed Web of Science ®Google Scholar
• ANKER SD, COATS AJ: How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int. J. CardioL (2002) 86:123–130.
   PubMed Web of Science ®Google Scholar
• MANN DL, MCMURRAY JJ, PACKER M, SWEDBERG K, BORER JS, COLUCCI WS: Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized etanercept worldwide evaluation (RENEWAL). Circulation (2004) 109:1594–1602.
   PubMed Web of Science ®Google Scholar
• KWON HJ, COTE TR, CUFFE MS, KRAMER JM, BRAUN MM: Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann. Intern. Med. (2003) 138:807–811.
   PubMed Web of Science ®Google Scholar
• WOLFE F, MICHAUD K: Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am. J. Med. (2004) 116:305–311.
   PubMed Web of Science ®Google Scholar
• EKSTROM K, HJALGRIM H, BRANDT Let al.: Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum. (2003) 48:963–970.
   Google Scholar
• GELFAND JM, BERLIN J, VAN VOORHEES A, MARGOLIS DJ: Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch. DermatoL (2003) 139:1425–1429.
   PubMed Web of Science ®Google Scholar
• BROWN SL, GREENE MH, GERSHON SK, EDWARDS ET, BRAUN MM: Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. (2002) 46:3151–3158.
   PubMed Web of Science ®Google Scholar
• ASKLING J, FORED CM, BAECKLUND E et al.: Hematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics following TNF-antagonists. Ann. Rheum. Dis. (2005) 64:1414–1420.
   PubMed Web of Science ®Google Scholar
• GEBOREK P, BLADSTROM A. TURESSON C, GULFE A, PETERSSON IF, SAXNIE T: Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann. Rheum. Dis. (2005) 64:699–703.
   PubMed Web of Science ®Google Scholar
• WOLFE F, MICHAUD K: The effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. (2004) 50:1740–1751.
   PubMed Web of Science ®Google Scholar
• STERN DK, TRIPP JM, HO VC, LEBWOHL M: The use of systemic immune moderators in dermatology: an update. DermatoL Clin. (2005) 23:259–300.
   PubMed Web of Science ®Google Scholar
• SCOTT DL: Etanercept in arthritis. Int. J. Clin. Pract. (2005) 59:114–118.
   PubMed Web of Science ®Google Scholar
• GOFFE B: Etanercept (Enbrel®) - an update. Skin Ther. Lett. (2004) 9:1-4,9.
   Google Scholar
• http://www.psoriasis.org/facts/psa National Psoriasis Foundation website.
   Google Scholar
• http://www.centocor.com/news/ news_051705.jsp Centocor website.
   Google Scholar